Our proprietary technology combines high-sensitivity mass spectrometry with advanced bioinformatics and machine learning to reveal the full complexity of HLA-presented peptides — enabling safer, more effective drug development. From tumor profiling to target validation and toxicity prediction, we turn deep biology into actionable insight.

Explore our core technology pillars.